MEDIPHAGE BIOCEUTICALS

661 University Ave., Suite 1300
MaRS Centre, West Tower
Toronto, Ontario, M5G 0B7

PRESS RELEASE

FOR IMMEDIATE RELEASE
July 15th, 2019

CONTACT: Farah
Business Development Associate
farah.elzarkout@mediphage.ca

Mediphage Bioceuticals, Inc. Closes $3.25M Round of Financing

Toronto, Ontario – Mediphage Bioceuticals, Inc., a genetic medicine company, developing safe, effective, and accessible therapeutics to unlock the power of ***personalized and redosable*** genetic medicine, announced that it has closed its $3.25M USD seed round of financing.

"2019 has been a key inflection year for Mediphage. The proceeds of this financing round will allow us to aggressively continue development of preclinical safety and effectiveness data required for our Stargardt's Disease IND (investigational new drug) regulatory approval, completion of two key feasibility studies related to immunogenicity, and advancement of work related to two strategic partnership agreements. With these funds in place, we are well positioned to meet milestones for development of the core msDNA technology and are pleased to have closed this financing round with participation from sophisticated, professional investors that are prepared to support the company well over the next three years of commercialization activity" said CEO of Mediphage.

Currently, Mediphage is advancing its internal therapeutic development program for Stargardt disease and has several strategic partnerships that are applying ministring (msDNA) for therapeutic development in the areas of chimeric antigen receptor T-Cells, induced pluripotent stem cells and multiple cancer primary cell lines.

About Mediphage

Mediphage Bioceuticals is a precision genetic medicine company with a mission to eradicate suffering from a wide range of chronic diseases through revolutionary therapeutics. The Toronto-based company, founded in January 2016 as a spin-off from the University of Waterloo, uses proprietary *E. Coli*-based manufacturing platforms to generate safe, effective and redosable gene delivery vectors called ministring DNA or msDNA. Mediphage's proprietary msDNA platform is an efficient, customizable, durable, and highly scalable, non-viral gene delivery vector which confers application to *in vivo* and *ex vivo* gene or cell therapies. Mediphage is focusing its internal efforts on developing a therapeutic for Stargardt Disease, an ocular inherited condition caused by a mutation of the large *ABCA4* gene. As a platform technology, msDNA has the potential for broad applicability to various gene or cell therapy and gene editing categories including T-cell and B-cell applications, DNA vaccines, iPSC, CRISPR and rAAV production.